Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Drug

Akeso Biopharma Initiates Phase III Clinical Trial for PD-1/VEGF Bispecific Antibody Combination

Fineline Cube Oct 31, 2024

China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first patient in a...

Company

AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience

Fineline Cube Oct 31, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter...

Company Drug

Shanghai Henlius and Organon Submit Biosimilar Application for Denosumab to FDA

Fineline Cube Oct 31, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) and its US partner Organon (NYSE: OGN) have jointly...

Company

Pfizer Reports Strong Q3 Results, Boosts 2024 Guidance to $61-$64 Billion

Fineline Cube Oct 30, 2024

Pfizer Inc. (NYSE: PFE) released its Q3 2024 financial results, reporting revenues of $17.702 billion...

Company Drug

AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV

Fineline Cube Oct 30, 2024

AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from...

Company Medical Device

Acotec Secures NMPA Approval for Acotrace Disposable Catheter Sheath

Fineline Cube Oct 30, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received marketing approval from the...

Company Deals

Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%

Fineline Cube Oct 30, 2024

Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which...

Company Medical Device

Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System

Fineline Cube Oct 30, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced the five-year follow-up...

Company Drug

Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients

Fineline Cube Oct 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its drug Scemblix (asciminib) has received accelerated...

Company Deals

MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions

Fineline Cube Oct 30, 2024

MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic...

Company Medical Device

Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges

Fineline Cube Oct 30, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing...

Company

BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards

Fineline Cube Oct 30, 2024

On October 25, Yin Min, Chief Commercial Officer of BeiGene (NASDAQ: BGNE) Greater China, was...

Company Deals

Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases

Fineline Cube Oct 30, 2024

U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop...

Company Drug

Yantai Dongcheng Pharma Secures FDA Fast-Track Designation for 177Lu-LNC1004 in Thyroid Cancer

Fineline Cube Oct 30, 2024

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...

Company Drug

Sunshine Guojian Pharmaceutical Secures NMPA Approval for Clinical Trials of SSGJ-626 in Lupus Indications

Fineline Cube Oct 30, 2024

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336) has announced that it has received...

Company Drug

Zai Lab Reports Positive Phase III Results for KarXT, Showcasing Efficacy in Psychiatric Conditions

Fineline Cube Oct 30, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced encouraging topline results from...

Company Drug

Sun-Novo Pharmaceuticals Gets Green Light for CAR-T Therapy Clinical Trial in Lupus Treatment

Fineline Cube Oct 30, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) has secured approval from China’s National Medical...

Company Deals

GSK Secures Global Rights to Chimagen Biosciences’ T Cell-Engager in $850 Million Deal

Fineline Cube Oct 30, 2024

UK pharmaceutical company GSK plc (NYSE: GSK) has entered into a licensing agreement with Chimagen...

Company

Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress

Fineline Cube Oct 30, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company

Shanghai Pharmaceuticals Reports Q3 2024 Revenue Growth, Strengthens Drug Pipeline

Fineline Cube Oct 30, 2024

China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the...

Posts pagination

1 … 299 300 301 … 689

Recent updates

  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
  • Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Company Drug

Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.